Sage Journals: Discover world-class research

Abstract

Feiduqing (FDQ) is a traditional Chinese medicine formula used for many years in the treatment of viral pneumonia (VP). However, the effective components of FDQ and the mechanism by which it affects VP remain unclear. The purpose of this study is to determine the multitarget mechanism of the effect of FDQ on VP through determination and in vivo pharmacodynamics combined with network pharmacology. Firstly, the compound–target–pathway network was constructed by using TCMSP, UniProt, GeneCards, STRING, and DAVID databases through Cytoscape 3.7.0. Secondly, the content of the effective components of the original prescription of FDQ was determined. Finally, the pharmacological activity of FDQ in vivo was verified by an animal model, and the active ingredient composition (AIC), selected by network pharmacology was used for antipyretic, antiinflammatory, antitussive, and expectorant symptoms. Seven compounds of FDQ and 22 potential target genes in the treatment of VP with FDQ were identified by network pharmacology analysis. Kyoto Encyclopedia of genes and genomes enrichment analysis results indicated that the mechanism of FDQ in the treatment of VP was mainly related to pathways in cancer, hepatitis b, tumor necrosis factor (TNF) signaling pathway, Chagas disease, tuberculosis, influenza A, human T-cell leukemia virus, type 1 infection, toxoplasmosis and toll-like receptor signaling pathways, osteoclast differentiation, nonalcoholic fatty liver disease, and leishmaniasis. The results of pharmacodynamic experiments showed that FDQ and AIC possessed antipyretic, cough relieving, and reducing sputum effects. Besides, FDQ and AIC could also significantly reduce the content of prostaglandin E₂, TNF-α, cyclic adenosine monophosphate, interleukin-1β, and myeloperoxidase in vivo, while increasing the content of interleukin-10 in vivo. The active ingredients of FDQ prescriptions could be accurately screened by network pharmacological analysis, as they clarified the mechanism of FDQ in the treatment of VP. The research results provided potential ideas and methods for the screening and purification of active ingredients in traditional Chinese medicine prescriptions.

Keywords

Feiduqing viral pneumonia network pharmacology pharmacodynamic experiment

Introduction

Viral pneumonia (VP) is an inflammation of the lungs caused by viral upper respiratory tract infection, which spreads downward and has symptoms of headache, fever, cough, and expectoration. Feiduqing (FDQ) is a prescription for clinical experience in the treatment of VP. It is composed of 3 herbal components: Oroxylum indicum (L.) Vent (Muhudie [MHD]), Gardenia jasminoides Ellis (Zhizi [ZZ]), and Sophora flavescens Ait (Kushen [KS]) in a weight ratio of 1:3:2. It has the effects of heat-clearing, detoxifying, and moisturizing lungs. FDQ also plays a positive role in relieving fever, cough, and irritability caused by VP. Modern pharmacological research of MHD¹ has studied its obvious inhibitory effect on inflammation. ZZ has the functions of heat-clearing, fire-purging, blood-cooling, and detoxifying.^2,3 Furthermore, ZZ contains a large amount of cyclic olefin ether terpenoids, organic acids, flavonoids, and other ingredients with antiinflammatory, antipyretic, analgesic, and antioxidative effects. KS has functions of heat-clearing, dampness-drying, bacteriostasis, and insect killing. In addition, because it contains a variety of active ingredients, it shows obvious antiinflammatory effects.⁴

Traditional Chinese medicine (TCM) refers to drugs used to prevent, treat, and diagnose diseases under the guidance of TCM theory. Chinese medicine is highly valued worldwide for its clinical efficacy and safety. TCM has significant antibacterial and other pharmacological effects.^5,6 Through the methods of multicomponents, multitargets, and multipathways, the action mechanism of TCM is described systematically based on its therapeutic function.⁷ At present, the technological route and quality control of TCMs are mostly based on chemical components, but the correlation of these with clinical safety and effectiveness is not yet clear, which may affect the efficacy of the drugs to a certain extent.⁸ Hopkins⁹ proposed the concept of “Network pharmacology” in 2007. With the emergence of multicomponent and multitarget modern drug development models, the advantages of TCM in the treatment of complex diseases have become increasingly prominent. The efficacy of TCM is the result of the interaction and mutual adjustment of the active ingredient group formed by multiple active ingredients in TCM and multiple disease-related targets. It is called active ingredient omics.^10,11 Network pharmacology is an emerging discipline based on the theory of systems biology. It conducts network analysis of biological systems, builds a “drug–target–disease” network relationship, and then select specific signal nodes to design multitarget drug molecules.¹² In this study, network pharmacology analysis was used to identify the possible mechanism of FDQ in VP treatment. The antipyretic, antitussive, and phlegm-reducing effects of FDQ and AIC suggested by the network analysis were further verified by in vivo biological experiments.

Materials and Methods

Screening of Chemical Ingredients in FDQ

The main chemical constituents of O indicum (L.) Vent (MHD), Gardenia jasminoides Ellis (ZZ), and S flavescens Ait (KS) were searched for using the TCM systems pharmacology database and analysis platform (TCMSP; http://lsp.nwu.edu.cn/tcmsp.php) and literature analysis in different platform databases. Higher oral bioavailability (OB) values generally indicate that the bioactive molecules of the drug have drug-likeness (DL). FDQ shows positive effects on the treatment of VP, mainly for oral administration. Therefore, the OB values ≥30% and DL values ≥0.18 were selected to screen the active ingredients of the 3 Chinese medicines in the TCMSP database.

Collection of Compound-Related Targets and VP-Related Targets

The target with a known chemical composition in FDQ has been screened by the target prediction function in the TCMSP database. The predicted targets of the compounds were screened and searched in the UniProt database (https://www.uniprot.org/). Uniprot (https://www.genecards.org/) database was used to import the names of proteins and limit the “species” to “Homo sapiens.” All retrieved protein targets were corrected to Uniprot ID and gene names corresponding to FDQ target proteins were obtained. VP-related targets were collected from GeneCards (https://www.genecards.org/).¹³

Construction and Analysis of the Protein–Protein Interaction (PPI) Network

The screened and disease targets were uploaded to Venny 2.1 (https://bioinfogp.cnb.csic.es/tools/venny/index.html) to obtain the intersection of the active compounds and targets of VP genes, as the active ingredients of FDQ in the treatment of VP. To explain further the mechanism of FDQ active ingredient targets and disease targets at the protein level, the potential target genes of FDQ for the treatment of VP were introduced into the protein interaction analysis platform STRING11.0 (https://string-db.org/) to obtain the relationship of protein interaction. Then, the “species” was set as “human,” and the PPI network map was obtained. PPIs were predicted through STRING11.0, including direct and indirect interactions between proteins, and the key points were highlighted and assigned to the information about each protein interaction. The higher the score, the more confident the target protein interactions were. Then, the results exported from the STRING11.0 were imported into the software of Cytoscape 3.7.0 for visual analysis and network analysis. Finally, the PPI network map was obtained from the comprehensive score reflected by color, degree value, size, and edge thickness.

Network Construction and Analysis

To observe further the biological function of targets, 49 compound targets and VP targets were imported into the DAVID v6.8 (https://david.ncifcrf.gov/) database for pathway enrichment analysis. The identifier was set to “OFFICIAL GENE SYMBOL,” the list type was set to “Gene List,” the species to “Human,” and the P-value <.05; the data were classified according to the P-value, and the pathways were sorted from high to low. The Kyoto Encyclopedia of genes and genomes (KEGG) pathway information of FDQ involved in the pathological process of VP was screened out. The KEGG pathway information with significant differences was screened out using the Omicshare database (http://www.omicshare.com) to draw an advanced bubble chart. Then, GraphPad Prism 6.0 was used to draw histograms.

According to the above target prediction results of FDQ for the treatment of VP, the FDQ component–target–pathway network model was constructed by the “merging” function of Cytoscape software. Compounds, targets, and pathways were represented by nodes in the network.

Preparation and Chemical Analysis of FDQ Extract

Materials

BS-6KH electronic scale was purchased from Shanghai Yousheng Weighing Apparatus Co., Ltd; DZTW electronic thermostat electric heating jacket was purchased from Tianjin Industrial Laboratory Instrument Co., Ltd; FA2004 Analytical Electronic Balance was purchased from Shanghai Liangping Instrumentation Co., Ltd; and Waters 2695 High-Performance Liquid Chromatograph was purchased from Waters.

The 3 herbs in FDQ were purchased from Beijing Tong Ren Tang Chinese Medicine Co. Ltd, quercetin (≥98% Lot no. 100081-299406) from China Institute for the Control of Pharmaceutical and Biological Products, matrine (≥98% Lot no. 519-02-8) from Chengdu Phytochemical Pure Biotechnology Co., Ltd, and kaempferol (≥98% Lot no. wkq19011609), aloe-emodin (≥98% Lot no. wkq19040302), ellagic acid (≥98% Lot no. wkq19010702), oroxylin a (≥98% Lot no. wkq19022608), and formononetin (≥98% Lot no. wkq19013002) from Sichuan Weikeqi Pharmaceutical Technology Co., Ltd.

Determination of Potential Active Constituents of FDQ

FDQ was extracted by traditional techniques to determine the content ratio of the active ingredients in the original prescription.

The 3 herbs in FDQ were mixed in a ratio of 1:3:2 (w/w/w). KS and MHD were extracted 3 times (1.5 h each time) by adding 10 times the amount of 70% ethanol. ZZ was extracted 3 times (1 h each time) by adding 12 times the amount of water. The water extract of ZZ was concentrated to a density of 1.20, and then it was precipitated with 85% ethanol for 24 h. After standing for 24 h, the precipitate was collected by filtration. To determine the content of each index and prepare FDQ ethanol (FDQA) extract, the ethanol extracts of KS and MHD were combined with the ZZ ethanol precipitated solution after water extraction. Then, the FDQ extract was filtered and concentrated by rotary evaporation. Finally, the extract was dried under reduced pressure and stored in a desiccator before use. The 3 Chinese medicinal materials were extracted by refluxing 3 times according to the prescription plus 12 times the amount of water for 1 h each time. The combined extract was concentrated by rotary evaporation and dried under reduced pressure to obtain FDQ water extract (FDQW).

For quercetin analysis, 10 µL of FDQA solution was prefiltered through a 0.45 μm Millipore filter and injected into a Supercell ODS-B C₁₈ column (250 mm × 4.6 mm, 5 μm). Linear gradient elution with acetonitrile (B) and 0.2% phosphoric acid (C) was carried out. The program was set as follows: time (min)/B (v/v):C (v/v); T_0.01/15:85, T₁₀/23:77, T₁₅/30:70, T₂₀/50:50, and T₂₂/15:85. The flow rate was 1.0 mL/min and the column temperature was kept constant at 35 °C. The detector was ultraviolet absorption (UV) and the detection was performed at 360 nm. For kaempferol analysis, the mobile phase was methanol (A) and 0.1% acetic acid (C). The composition of the eluent was 30% methanol in the first 72 min, 30%-100% methanol from 72 to 76 min, 100% methanol from 76 to 78 min, 100%-30% methanol from 78 to 80 min, 30% methanol from 80 to 85 min. The column temperature was maintained at 30 °C and the detection wavelength was 270 nm. The other analytical conditions were the same as the above quercetin analysis. For matrine analysis, the mobile phase was acetonitrile (B) and 0.05 mol/L potassium dihydrogen phosphate (C) (containing triethylamine 2.0 mL/L). The gradient elution procedure was as follows: time (min)/B (v/v):C (v/v); T_0.01/6:94, T₁₂/10:90, and T₄₅/10:90. The column temperature was 30 °C, and the detection wavelength was set at 220 nm. Other conditions were the same as above. For aloe-emodin analysis, the mobile phase was the same as for kaempferol. The gradient elution procedure was as follows: time (min)/A (v/v):C (v/v); T_0.01/72:28, T_6.5/92:8, T_22.5/72:28, and T₃₀/72:28. The detection wavelength was 270 nm. Other conditions were the same as for the determination of kaempferol. For formononetin analysis, a linear gradient elution of acetonitrile (B) and 0.01% phosphoric acid (C) was used. The program was as follows: time (min)/B (v/v):C (v/v); T_0.01/30:70, T₁₂/33:67, T₁₃/40:60, and T₂₅/40:60. Except for the detection wavelength of 248 nm, the other conditions were the same as those for kaempferol content determination.

Quercetin, kaempferol, matrine, aloe-emodin, and formononetin were mixed as the active ingredient composition (AIC) according to the ratio of the above measurement results.

Pharmacological Verification on Network Analysis

Materials

Codeine phosphate (CP) (Lot no. 20180433) was supplied by Qinghai Pharmaceutical Factory Co., Ltd, bromhexine hydrochloride (BH) by Zhejiang Wanbang Pharmaceutical Co., Ltd, aspirin effervescent tablets (Lot no. 1903009) by Astra Zeneca Pharmaceutical Co., Ltd, emergency branch syrup (EBS) (Lot no. 18110256) by Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd, and Lianhua Qingwen Capsule (LHQW-C) (Lot no. A1811006) by Shijiazhuang Yiling Pharmaceutical Co., Ltd. All other reagents were of analytical grade or higher. Prostaglandin E₂ (PGE₂), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-10 (IL-10) Elisa kit, and cyclic adenosine monophosphate (cAMP) and myeloperoxidase (MPO) kits were purchased from Jiangsu Meimian industrial Co., Ltd.

Animals

Sprague–Dawley rats (180-200 g, 5-6 weeks old) and specific-pathogen-free mice (18-20 g, 4 weeks old) were supplied by Chengdu Dashuo Technology Co., Ltd, and maintained according to the Guidelines for the Care and Use of Laboratory Animals. All animal research and experimental protocols were approved by the Institutional Animal Experiment Committee of Chengdu University (SCXK [Sichuan Province, China] 2015-030).

Animal Treatment and Tissue Preparation

Four days before the experiment, the rats and mice were provided water and food freely under laboratory conditions.

Antipyretic effect: Ten grams of chloral hydrate was dissolved in 100 mL of physiological saline to obtain 10% chloral hydrate solution. Lipopolysaccharide (LPS) solution (10 mg of LPS in 1 L of physiological saline) was prepared under sterile conditions.

Before grouping, the anal temperature was measured at 9:00 and 16:00 for 3 consecutive days, and the average of 6 consecutive body temperatures was taken as the basal body temperature (T₀). Rats with a body temperature of >38 °C or a temperature difference of >0.5 °C were excluded. Rats were randomly divided into control group (10 mL/kg), aspirin group (330 mg/kg), LHQW-C group (420.0 mg/kg), FDQW group (460.0 mg/kg), FDQA group (336.2 mg/kg), and AIC group (19.10 mg/kg). Rats in each group were continuously administered for 7 days at the above doses. The control group was administrated orally with water at the same time. LHQW-C, FDQW, FDQA, and AIC suspensions were prepared by dissolving crude drugs and 0.6% sodium carboxymethylcellulose in purified water. Thirty minutes after the last dose, rats were injected subcutaneously with 10 μg/100 g of LPS. After injection, the anal temperature of rats was measured at 0, 1.0, 2.0, 3.0, and 4.0 h. The changes in body temperature were recorded (T = T₁–T₂). T is the body temperature change value, T₁ is the body temperature after heating, and T₂ is the body temperature before administration. After measuring all the anal temperatures, the rats were executed, and their abdominal aorta blood and liver were taken. The activities of PGE₂, TNF-α, IL-1β, and cAMP in rat serum and the activity of MPO in liver homogenate were measured.

Antitussive effect: The screened mice were randomly divided into 6 groups: control group, CP group (12 mg/kg), EBS group (20 mL/kg), FDQW group (920.0 mg/kg), FDQA group (672.4 mg/kg), and AIC group (38.2 mg/kg). An ammonia cough test was performed about 1 h after administration, and the cough latency of the mice and the number of coughs within 2 min were recorded.¹⁴ Blood from the mice was collected from the orbit. IL-10 activity of serum was measured according to the manufacturer's recommendations using an Elisa kit.

Expectoration effects: Mice were randomly divided into control group (10 mL/kg), BH group (4.8 mg/kg), EBS group (20 mL/kg), FDQW group (920.0 mg/kg), FDQA group (672.4 mg/kg), and AIC group (38.2 mg/kg). Mice were sacrificed after 7 days’ administration and the trachea was removed. The phenol red secretory volume of the windpipe was observed.¹⁵

Statistics

Statistical analysis was performed using SPSS 20.0 (IBM). The statistical results of each group were compared with each other using analysis of variance, and the statistical significance was set to a P-value of <.05.

Results

Screening of Chemical Constituents of FDQ

Thirty-two active compounds were identified in FDQ after eliminating the duplicates from the TCMSP database (Table 1).

Table 1.

Compounds and Molecular Details.

Molecule ID	Molecule name	OB (%)	DL	Reference
MOL001040	(2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one	42.36	0.21	¹⁶
MOL001484	Inermine	75.18	0.54	¹⁷
MOL003627	Sophocarpine	64.26	0.25	¹⁸
MOL003648	Inermin	65.83	0.54	¹⁹
MOL003673	Wighteone	42.80	0.36	²⁰
MOL003680	Sophoridine	60.07	0.25	²¹
MOL000392	Formononetin	69.67	0.21	²²
MOL004580	cis-Dihydroquercetin	66.44	0.27	²³
MOL005100	5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one	47.74	0.27	²⁴
MOL005944	Matrine	63.77	0.25	²⁵
MOL006596	Glyceollin	97.27	0.76	²⁶
MOL003347	Hyperforin	44.03	0.60	²⁷
MOL006613	Kushenin	47.62	0.38	²⁸
MOL006620	Kushenol J	50.86	0.24	²⁹
MOL006623	Kushenol t	51.28	0.64	³⁰
MOL006626	Leachianone g	60.97	0.40	³¹
MOL006630	Norartocarpetin	54.93	0.24	³²
MOL000456	Phaseolin	78.20	0.73	³³
MOL006650	(-)-Maackiain-3-O-glucosyl-6′-O-malonate	48.69	0.52	³⁴
MOL001002	Ellagic acid	43.06	0.43	³⁵
MOL012108	Negletein	41.16	0.23	³⁶
MOL002776	Baicalin	40.12	0.75	³⁷
MOL002928	Oroxylin a	41.37	0.23	³⁸
MOL004004	6-OH-luteolin	46.93	0.28	³⁹
MOL000449	Stigmasterol	43.83	0.76	⁴⁰
MOL000471	Aloe-emodin	83.38	0.24	⁴¹
MOL000098	Quercetin	46.43	0.28	⁴²
MOL004561	Sudan III	84.07	0.59	⁴³
MOL000422	Kaempferol	41.88	0.24	⁴⁴
MOL001494	Mandenol	42.00	0.19	⁴⁵
MOL001942	Isoimperatorin	45.46	0.23	⁴⁶
MOL007245	3-Methylkaempferol	60.16	0.26	⁴⁷

Abbreviations: OB, oral bioavailability; DL, drug-likeness.

Construction of Target Protein Interaction Network for FDQ in the Treatment of VP

As shown in Figure 1, there are 49 targets between 209 compound-related targets and 300 VP-related targets. The 49 shared targets of the PPI network map generated by the STRING database possessed high confidence scores, indicating a strong correlation between these targets. The PPI network of these 47 shared targets is depicted in Figure 2. The potential target information is shown in Table 2. Topology analysis indicated that TNF, IL-6, RELA, JUN, mitogen-activated protein kinase 1 (MAPK1), IL-1β, C-X-C motif chemokine-8 (CXCL8), TP53, AKT1, and C-C motif chemokine 2 (CCL2) were the top 10 shared targets based on degree centrality.

Figure 1.

Distribution of FDQ potential targets and VP targets.

Figure 2.

The network of the shared targets between FDQ potential targets and VP targets. The color of nodes is proportional to the degree centrality by topology analysis.

Table 2.

Potential Target Information.

Gene symbol	Uniprot number	Target name
PTGS2	P35354	Prostaglandin G/H synthase 2
LACTB	P83111	Beta-lactamase
TNF	P01375	Tumor necrosis factor
IL6	P05231	Interleukin-6
JUN	P05412	Transcription factor AP-1
IL4	P05112	Interleukin-4
RELA	Q04206	Transcription factor p65
MMP2	P08253	72 kDa type IV collagenase
CASP3	P42574	Caspase-3
MYC	P01106	Myc proto-oncogene protein
ICAM1	P05362	Intercellular adhesion molecule 1
CXCL8	P10145	Interleukin-8
EGFR	P00533	Epidermal growth factor receptor
AKT1	P31749	RAC-alpha serine/threonine-protein kinase
VEGFA	P15692	Vascular endothelial growth factor A
CCND1	P24385	G1/S-specific cyclin-D1
BCL2	P10415	Apoptosis regulator Bcl-2
FOS	P01100	Proto-oncogene c-Fos
BAX	Q07812	Apoptosis regulator BAX
MMP9	P14780	Matrix metalloproteinase-9
MAPK1	P28482	Mitogen-activated protein kinase 1
IL10	P22301	Interleukin-10
TP53	P04637	Cellular tumor antigen p53
CASP8	Q14790	Caspase-8
RAF1	P04049	Rapidly accelerated fibrosarcoma proto-oncogene serine/threonine-protein kinase
SOD1	P00441	Superoxide dismutase [Cu-Zn]
MMP1	P03956	Interstitial collagenase
STAT1	P42224	Signal transducer and activator of transcription 1-alpha/beta
F3	P13726	Tissue factor
IL1β	P01584	Interleukin-1beta
CCL2	P13500	C-C motif chemokine 2
VCAM1	P19320	Vascular cell adhesion protein 1
TGFB1	P01137	Transforming growth factor beta-1
IL2	P60568	Interleukin-2
PLAT	P00750	Tissue-type plasminogen activator
SERPINE1	P05121	Plasminogen activator inhibitor 1
IFNG	P01579	Interferon gamma
PTEN	P60484	Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase
IL1A	P01583	Interleukin-1 alpha
MPO	P05164	Myeloperoxidase
NCF1	P14598	Neutrophil cytosol factor 1
CXCL2	P19875	C-X-C motif chemokine 2
CRP	P02741	C-reactive protein
CXCL10	P02778	C-X-C motif chemokine 10
SPP1	P10451	Osteopontin
CD40LG	P29965	CD40 ligand
IRF1	P10914	Interferon regulatory factor 1
IKBKB	O14920	Inhibitor of nuclear factor kappa-B kinase subunit beta
MAPK8	P45983	Mitogen-activated protein kinase 8

Abbreviations: AP-1, activator protein 1; BAX, bcl-2-associated X protein.

Bioinformatics Analysis for FDQ in the Treatment of VP

Gene ontology (GO) and KEGG enrichment analysis were conducted on the corresponding targets of active components of FDQ using the DAVID database, and a threshold value of P < .05 was set. The most important biological processes (BPs) or pathways were screened and plotted using GraphPad Prism. GO enrichment analysis refers to a directed acyclic graph composed of the number of proteins or genes at a certain functional level, including 3 branches of BPs, cellular components (CCs), and molecular functions (MFs). Cytokine-mediated signaling pathway, response to cytokine, and cellular response to cytokine stimulus ranked first in Figure 3 (BP). Extracellular space, extracellular region part, and extracellular region ranked first in Figure 4 (CC). Cytokine receptor binding, cytokine activity, and signaling receptor binding are the top ones in Figure 5 (MF). Besides, the KEGG pathway enrichment analysis showed that these 49 key targets contributed to 198 pathways (P-value <.05). The top 20 pathways closely related to the mechanism of FDQ in the treatment of VP are shown in Figures 6 and 7.

Figure 3.

Enriched genes for BP as the potential targets of main active ingredients of FDQ to treat VP.

Figure 4.

Enriched genes for CC as the potential targets of main active ingredients of FDQ to treat VP.

Figure 5.

Enriched genes for MF as the potential targets of main active ingredients of FDQ to treat VP.

Figure 6.

Enriched gene for KEGG as the potential targets of main active ingredients of FDQ to treat VP.

Figure 7.

KEGG enrichment analysis of FDQ to treat VP.

The component–target–pathway network of FDQ treating VP was constructed by using the “merge” function of Cytoscape. As shown in Figure 8, the main active ingredients of FDQ were distributed in different pathways and coordinated with each other to adjust the effects of FDQ in the treatment of VP.

Figure 8.

The component-target-pathway network construction for 20 pathways and 37 compounds in Feiduqing (FDQ) and 41 candidate protein targets. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).

As shown in Figure 8, there were 137 nodes and 572 edges in this interaction network. Red rectangle nodes represent active ingredients, light green circles represent targets, and yellow arrows represent signal pathways. Degree, average shortest path length (ASPL), betweenness centrality (BC), and closeness centrality (CC) were ordered to determine the key nodes (Table 3). In the network, the components, targets, and signal pathways of which degree was greater or equal to median (component median was 1, target median was 10, and pathway median was 13) are shown in Table 3. Specifically, according to the degree of topological analysis and BC, quercetin, kaempferol, matrine, aloe-emodin, ellagic acid, oroxylin a, and formononetin are predicted to be important active compounds, indicating their critical roles in FDQ. In addition, prostaglandin-endoperoxide synthase 2 (PTGS2), IL-6, TNF, RELA, JUN, AKT1, and TP53 represented the crucial targets of FDQ based on degree and BC. Furthermore, most of these target proteins were enriched in pathways in cancer, hepatitis B, TNF signaling pathway, Chagas disease, tuberculosis, influenza A, human T-cell leukemia virus, type I infection, toxoplasmosis, and toll-like receptor signaling pathway.

Table 3.

Key Node Related Information.

Category	ID/Name	ASPL	BC	CC	Degree
Compound	MOL000098/quercetin	2.03676471	0.11536503	0.49097473	38
Compound	MOL000422/kaempferol	2.30147059	0.0233529	0.43450479	14
Compound	MOL005944/matrine	2.59558824	0.00301375	0.38526912	7
Compound	MOL000471/aloe-emodin	2.57352941	0.00274196	0.38857143	6
Compound	MOL001002/ellagic acid	3	1.56E-04	0.33333333	5
Compound	MOL002928/oroxylin a	2.54411765	0.00230758	0.39306358	4
Compound	MOL000392/formononetin	2.69117647	0.00194722	0.3715847	3
Target	PTGS2	2.00735294	0.36289659	0.4981685	36
Target	IL6	1.93382353	0.17306661	0.51711027	30
Target	TNF	2.05882353	0.0746173	0.48571429	29
Target	RELA	2.44852941	0.0142602	0.40840841	24
Target	JUN	2.38970588	0.01376582	0.41846154	22
Target	AKT1	2.36029412	0.07768808	0.42367601	19
Target	TP53	2.33088235	0.01966408	0.42902208	17
Target	MAPK1	2.36764706	0.02280819	0.42236025	16
Target	CXCL8	2.26470588	0.02388446	0.44155844	16
Target	VEGFA	2.26470588	0.02358877	0.44155844	15
Target	FOS	2.52941176	0.00269099	0.39534884	14
Target	IL4	2.49264706	0.02520017	0.40117994	14
Target	CCL2	2.47058824	0.00365699	0.4047619	14
Target	ICAM1	2.32352941	0.05323163	0.43037975	14
Target	MYC	2.56617647	0.00333084	0.38968481	13
Target	MAPK8	2.72794118	0.00173121	0.36657682	12
Target	IL10	2.5	0.00235377	0.4	12
Target	IL2	2.47058824	0.00270925	0.4047619	12
Target	STAT1	2.55147059	0.00323574	0.39193084	11
Target	IFNG	2.56617647	0.00166405	0.38968481	11
Target	BCL2	2.66176471	0.00278349	0.37569061	10
Target	EGFR	2.52205882	0.01464566	0.39650146	10
Pathway	Pathways in cancer	2.23529412	0.15443923	0.44736842	25
Pathway	Hepatitis B	2.36764706	0.0373575	0.42236025	21
Pathway	TNF signaling pathway	2.70588235	0.044915	0.36956522	18
Pathway	Chagas disease (American trypanosomiasis)	2.42647059	0.04236496	0.41212121	17
Pathway	Tuberculosis	2.45588235	0.01894697	0.40718563	15
Pathway	Influenza A	2.75	0.01306501	0.36363636	15
Pathway	HTLV-I infection	2.74264706	0.02954606	0.36461126	15
Pathway	Toxoplasmosis	2.44852941	0.02658929	0.40840841	14
Pathway	Toll-like receptor signaling pathway	2.47058824	0.03096534	0.4047619	14
Pathway	Osteoclast differentiation	2.77205882	0.01572444	0.36074271	13
Pathway	NAFLD	2.48529412	0.0124346	0.40236686	13
Pathway	Leishmaniasis	2.82352941	0.01870161	0.35416667	13

Abbreviations: ASPL, average shortest path length; BC, betweenness centrality; CC, closeness centrality; PTGS2, prostaglandin-endoperoxide synthase 2; IL6, interleukin 6; TNF, tumor necrosis factor; MAPK1, mitogen activated protein kinase 1; CXCL8, C-X-C motif chemokine-8; VEGFA, vascular endothelial growth factor A; IL4, interleukin 4; CCL2, C-C motif chemokine 2; ICAM1, intercellular adhesion molecule 1; MAPK8, mitogen activated protein kinase 8; IL10, interleukin 10; IL2, interleukin 2; STAT1, Signal transducer and activator of transcription 1; IFNG, interferon gamma; EGFR, epidermal growth factor receptor; HTLV-I; human T-cell leukemia virus, type I; NAFLD, non-alcoholic fatty liver disease.

Determination of Potential Active Constituents of FDQ

The extraction yield of FDQA was 18.7% (w/w) and of FDQW was 25.5% (w/w). The contents of quercetin, kaempferol, matrine, aloe-emodin, and formononetin in the FDQ extract were 0.41%, 0.01%, 1.0%, 0.03%, and 0.07% (w/w), respectively.

Pharmacological Verification

Antipyretic Effect

Compared with the control group, the aspirin FDQW groups could significantly inhibit the fever caused by the LPS solution in rats, and the values for each group were lower than that of the control group at 1 h. At the second hour, the body temperature of the rats was significantly suppressed in all groups except the FDQA group. The body temperature of the rats was significantly inhibited in all groups at 3 and 4 h compared with the control group. The results are shown in Figure 9 and Table 4. In summary, LPS-induced fever in the rats was effectively suppressed in the AIC group, the effect being comparable to that in the FDQW and FDQA groups. As depicted in Figure 10 and Table 5, compared with the control group, the levels of PGE₂, TNF-α, cAMP, IL-1β, and MPO in the serum of fever rats in the LHQW-C, FDQW, FDQA, and AIC group decreased to varying degrees (P < .05 and P < .01), and all of them showed obvious pharmacological effects.

Figure 9.

Changes in body temperature in all groups.

Figure 10.

PGE₂, TNF-α, cAMP, IL-1β, and MPO activity. (A) The effect on the level of PGE2 in serum of rats. (B) The effect on the level of TNF-α in serum of rats. (C) The effect on the level of cAMP in serum of rats. (D) The effect on the level of IL-1β in serum of rats. (E) The effect on the level of MPO in serum of rats.

Table 4.

Effect of FDQ on LPS-Induced Fever in Rats (x ± s, n = 10).

Time	Group
	Changes in anal temperature in rats (Δt, °C)
	0 h	1 h	2 h	3 h	4 h
Control	−0.08 ± 0.37	0.43 ± 0.67	0.56 ± 0.59	0.82 ± 0.36	1.14 ± 0.51
Aspirin	−0.01 ± 0.38	−0.79 ± 0.58**	−0.74 ± 0.77**	−0.51 ± 0.59**	−0.27 ± 0.43**
LHQW-C	−0.02 ± 0.85	−0.01 ± 0.78	−0.09 ± 0.80*	0.19 ± 0.55**	0.20 ± 0.70**
FDQW	−0.05 ± 0.40	−0.34 ± 0.43**	−0.13 ± 0.45*	0.27 ± 0.34**	0.16 ± 0.37**
FDQA	−0.08 ± 0.35	0.01 ± 0.37	0.17 ± 0.36	0.07 ± 0.33**	0.24 ± 0.44**
AIC	0.03 ± 0.37	0.03 ± 0.73	0.02 ± 0.40*	0.11 ± 0.33**	0.14 ± 0.21**

Abbreviations: FDQ, Feiduqing; LPS, lipopolysaccharide; LHQW-C, Lianhua Qingwen Capsule; FDQW, FDQ water extract; FDQA, FDQ ethanol; AIC, active ingredient composition.

*P < .05 compared with control group.

**P < .01 compared with control group. ***P < .001 compared with control group.

Table 5.

Effects of Integration Processing of FDQ Water Extract, Ethanol Extract, and AIC on PGE₂, TNF-α, cAMP, IL-1β and MPO Levels of LPS Induced Fever Rats.

Group	PGE₂ (ng/L)	TNF-α (ng/L)	cAMP (pg/mL)	IL-1β (ng/L)	MPO (ng/L)
Control	543.7 ± 96.3	451.3 ± 51.7	616.1 ± 113.3	49.6 ± 4.1	63.0 ± 5.6
Aspirin	473.4 ± 31.9***	387.5 ± 35.5**	513.6 ± 59.8**	43.3 ± 2.6*	55.9 ± 6.5*
LHQW-C	486.1 ± 28.9*	400.7 ± 27.3**	518.3 ± 101.0**	44.4 ± 5.1*	53.8 ± 7.4**
FDQW	493.8 ± 14.3*	371.9 ± 47.3**	513.0 ± 37.7**	44.1 ± 4.9*	56.83 ± 7.6*
FDQA	492.3 ± 59.5*	411.5 ± 47.2*	523.5 ± 55.1*	45.7 ± 4.7	56.1 ± 7.1*
AIC	496.3 ± 47.2*	392.6 ± 31.1**	495.0 ± 84.9**	45.1 ± 6.7*	56.1 ± 7.2*

Abbreviations: FDQ, Feiduqing; AIC, active ingredient composition; PGE₂, prostaglandin E₂; TNF-α, tumor necrosis factor-α; cAMP, cyclic adenosine monophosphate; IL-1β, interleukin-1β; MPO, myeloperoxidase; LPS, lipopolysaccharide; LHQW-C, Lianhua Qingwen Capsule; FDQW, FDQ water extract; FDQA: FDQ ethanol. *P < .05 compared with control group. **P < .01 compared with control group. ***P < .001 compared with control group.

Antitussive Effect

As shown in Figure 11 and Table 6, compared with the control group, the cough latency of the mice was significantly prolonged in the EBS, FDQW, and AIC groups (P < .01). Also, certain effects were observed in the CP and FDQA groups (P < .05). The number of coughs in mice was significantly decreased in the FDQW, FDQA, AIC, and EBS groups. The activity of IL-10 in the serum of mice in each group was significantly increased compared with the control group (Figure 12 and Table 7). Therefore, the cough latency induced by ammonia in mice was prolonged, the number of coughs was reduced, and the activity of IL-10 in the serum of mice was enhanced after gavage with FDQW, FDQA, or AIC.

Figure 11.

Latent period and cough times of mice. (A) The latent period of mice in different groups. (B) The cough times of mice in different groups.

Figure 12.

Interleukin-10 (IL-10) concentration in mouse serum of each group.

Table 6.

Effects of Ammonia on Cough in Mice.

Group	Latent period (s)	Cough times
Control	56.8 ± 31.0	34 ± 16
CP	93.3 ± 27.2*	23 ± 10*
EBS	113.5 ± 311.9**	7 ± 7**
FDQW	99.1 ± 44.6**	15 ± 10**
FDQA	90.3 ± 13.0*	13 ± 5**
AIC	101.7 ± 41.7**	10 ± 8**

Abbreviations: CP, codeine phosphate; EBS, emergency branch syrup; FDQW, FDQ water extract; FDQA, FDQ ethanol; AIC, active ingredient composition. *P < .05 compared with control group. **P < .01 compared with control group. ***P < .001 compared with control group.

Table 7.

IL-10 Results for Each Group.

Group	IL-10 (ng/L)
Control	202.0 ± 28.6
BH	226.1 ± 19.7*
EBS	232.3 ± 33.6*
FDQW	229.6 ± 29.7*
FDQA	230.8 ± 28.3*
AIC	231.8 ± 27.0*

Abbreviations: IL-10, interleukin-10; BH, bromhexine hydrochloride; EBS, emergency branch syrup; FDQW, FDQ water extract; FDQA, FDQ ethanol; AIC, active ingredient composition. *P < .05 compared with control group. **P < .01 compared with control group. ***P < .001 compared with control group.

Expectoration Effects

The results showed that the phenol red excretion of mice was significantly increased in the FDQW, FDQA, and AIC groups compared with the control group (Table 8 and Figure 13). In summary, the AIC screened by network pharmacology possessed the effect of reducing sputum.

Figure 13.

Phenol red concentration in mice trachea.

Table 8.

The Phenol Red Concentration in Each Group.

Group	Phenol red concentration (μg/mL)
Control	0.24 ± 0.07
CP	1.18 ± 0.78*
EBS	1.10 ± 0.87*
FDQW	1.68 ± 0.59**
FDQA	1.10 ± 0.20*
AIC	1.47 ± 0.79**

Discussion

FDQ is a combined formula of MHD, ZZ, and KS, which is widely used in the treatment of VP. The quality standard of FDQ's original medicinal materials have been studied and the FDQ extraction process through anti-virus test in vitro, anti-inflammatory, antipyretic, and analgesic effects in vivo have been preliminarily screened in the previous stage. Besides, the extraction, concentration, drying, and molding process research have also been optimized by our research group.^48–52 In addition, we screened 6 active ingredients for VP in FDQ through internet pharmacology, including quercetin, kaempferol, matrine, aloe-emodin, and formononetin, and then the observed effects of these ingredients on animals were compared with FDQ water and ethanol extracts.

In this study, the traditional efficacy of FDQ was selected to observe the relevant indicators of antipyretic, antiinflammatory, antitussive, and phlegm-resolving effects. Among them, PGE₂ is the most important medium related to thermoregulation.⁵³ Similarly, it was discovered that cAMP becomes one of the currently validated central heating media. IL-1β is an important cytokine involved in a variety of pyrogenic fevers.⁵⁴ TNF-α is an endogenous pyrogen, which can significantly increase the central mediator of PGE₂, and then induce fever in the hypothalamus. Furthermore, it can directly stimulate the thermoregulatory center or indirectly induce macrophages to secrete a large amount of IL-1β, causing fever.⁵⁵ MPO remains relatively constant in individual inflammatory cells. Activated neutrophils and macrophages will be released when inflammation occurs.^56,57 Therefore, the degree of tissue inflammatory cell infiltration can be determined indirectly by MPO content.⁵⁸ In this study, it was found that in the in vivo antipyretic experiment, the contents of PGE₂, TNF-α, cAMP, IL-1β, and MPO in the control group were significantly increased, while those of FDQW, FDQA, and AIC groups were significantly reduced when the body temperature decreases. Therefore, it could be speculated that FDQ and AIC can relieve heat through the center, and exert the antipyretic effect by inhibiting the peripheral liver tissue inflammation. IL-10 is an important antiinflammatory factor, which plays a role by inhibiting the release of inflammatory factors from monocytes and various immune cells. From the results of the antitussive experiment, we found that the amount of IL-10 in FDQ and AIC increased significantly, indicating that both FDQ and AIC can inhibit inflammation to a certain extent. The effective ingredients of TCM are not easy to determine because of their complex composition. To ensure the effectiveness of the medicine, the dosage form of the decoction is commonly used. The effective ingredients should be taken together with other noneffective ingredients, resulting in a much larger dosage. Therefore, it cannot be developed into modern dosage forms due to the limitation of drug loading. Network pharmacology is a new discipline based on the basic theories of systems biology which conducts a comprehensive analysis of biological systems and further obtains the specific node with multiple targets. The network analysis based on a wide range of databases enables us to form a preliminary understanding of the mechanism of drugs. The main effective ingredients of FDQ, such as quercetin, kaempferol, matrine, aloe-emodin, and formononetin were screened by network pharmacology. According to the content of the original medicinal materials, the main pharmacodynamics and mechanism of the original prescription were compared by the method of “composition reduction.” The results showed that AIC was equivalent to FDQW and FDQA, which showed that network pharmacology can accurately screen the effective ingredients. The results provided a potential idea and method for the screening and purification of the effective ingredients of TCM. However, our research only predicted and validated 1 disease at present. In the future, other pathogenic mechanisms related to FDQ should be further studied, such as quantitative polymerase chain reaction, Western blot to confirm the pathogenic mechanisms and targets discovered by network pharmacology.

Conclusion

In this study, the main active ingredients in FDQ in the treatment of VP were screened by a network pharmacology method and the drug–disease–target interrelationships and mechanisms were confirmed. The pharmacological activities of FDQ and AIC were verified in vivo. The results showed that pharmacological activity was consistent between the components screened by network pharmacology and FDQ, and contents of PGE₂, TNF-α, cAMP, IL-1β, and MPO in rats were suppressed while the content of antiinflammatory factor IL-10 was increased.

Footnotes

Author Contributions

TL contributed to the design of this study and the revision of the manuscript. QL and YLX conducted the experiments. BWL and HY drafted the main manuscript. HBM and ADY performed data analysis. YZH drew the picture in the manuscript. All the authors participated in the interpretation of the results. All the authors have read and approved the final manuscript.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Sichuan Science and Technology Program (No. 2020YJ0477), the National Key R&D Program of China (2017YFC1701900), and the Technology Innovation R&D Project of Chengdu Science and Technology Bureau in 2021 (2021-YF05-00080-SN).

Ethical Approval

This study was approved by the Administration Committee of Experimental Animals, Sichuan Province, China.

Statement of Human and Animal Rights

All of the experimental procedures involving animals were conducted in accordance with the Institutional Animal Care Guidelines of Chengdu University, China and approved by the Administration Committee of Experimental Animals, Sichuan Province, China.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

Trial Registration

Not applicable, because this article does not contain any clinical trials.

ORCID iD

Tao Liu

References

Pan

. Hypotensive effect study of Oroxylum indicum (L.) Vent on SHR rats (in Chinese). Chin Mod Med. 2019;26(09):34-37.

Shi

Kong

, et al. Research progress on chemical composition and pharmacological effects of Gardenia jasminoides and predictive analysis on quality marker (Q-marker) (in Chinese). Chin Trad Herb Drugs. 2019;50(02):281-289.

Huang

. Gardenia jasminoides Ellis inhibit white spot syndrome virus replication in red swamp crayfish Procambarus clarkia. Aquaculture. 2019;504(04):239-247.

Chen

Yang

Hao

, et al. A novel flavonoid kushenol Z from Sophora flavescens mediates mTOR pathway by inhibiting phosphodiesterase and Akt activity to induce apoptosis in non-small-cell lung cancer cells. Molecules. 2019;24(24):4425.

Pejin

Bianco

Newmaster

, et al. Fatty acids of Rhodobryum ontariense (Bryaceae). Nat Prod Res. 2012;26(8):696-702.

Pejin

Tommonaro

Iodice

, et al. A new depsidone of Lobaria pulmonaria with acetylcholinesterase inhibition activity. J Enzyme Inhib Med Chem. 2012;28(4):876-878.

Xiang

Zhao

, et al. Network pharmacology-based identification for therapeutic mechanism of Ling-Gui-Zhu-Gan decoction in the metabolic syndrome induced by antipsychotic drugs. Comput Biol Med. 2019;110(07):1-7.

Liu

Zhang

Yao

, et al. Re-evaluation of Shuanghuanglian series preparations based on pharmacodynamics action value (in Chinese). Chin Trad Herb Drugs. 2019;50(04):903-909.

Hopkins

. Network pharmacology. Nat Biotechnol. 2007;25(10):1110-1111.

10.

Wang

Cui

Dai

, et al. HuangQin decoction attenuates CPT-11-induced gastrointestinal toxicity by regulating bile acids metabolism homeostasis. Front Pharmacol. 2017;8(156):1-11.

11.

Dai

Cui

Wang

. Systems pharmacology based strategy for Q-markers discovery of HuangQin decoction to attenuate intestinal damage. Front Pharmacol. 2018;9(236):1-8.

12.

Zeng

Siu

, et al. A combined molecular biology and network pharmacology approach to investigate the multi-target mechanisms of Chaihu Shugan San on Alzheimer’s disease. Biomed Pharmacother. 2019;120(12):109370.

13.

Zhu

Zhang

, et al. Network pharmacology-based identification of protective mechanism of Panax Notoginseng Saponins on aspirin induced gastrointestinal injury. Biomed Pharmacother. 2018;105(09):159-166.

14.

Wang

Chen

Jiang

. Effects of couplet medicines Fritillaria thunbergii and Rhizoma anemarrhenae on relieving cough, eliminating phlegm and relieving asthma (in Chinese). Chin J Tradit Chin Med Pharm. 2019;34(6):2474-2476.

15.

Sun

. Mechanism Study on Treatment of Acute Bronchitis of Bulbus Fritillariae Cirrhosae Cough Relieving Granule (in Chinese) . MS thesis. Chengdu University of Traditional Chinese Medicine; 2011.

16.

Brandt

Bekker

Ferreira

. Structure and absolute configuration of biflavonoids with benzofuranoid constituent units. In: Gross

Hemingway

Yoshida

Branham

, eds. Plant Polyphenols 2. Basic Life Sciences. Springer; 1999:245-246.

17.

Gustine

Moyer

. Retention of phytoalexin regulation in legume callus cultures. Plant Cell Tiss Organ Cult. 1981;1(1):255-263.

18.

Qavi

Wyde

Khan

. In vitro inhibition of HHV-6 replication by sophocarpines. Phytother Res. 2002;16(2):154-156.

19.

Ali

Munam

, et al. Genomics of Plant, Soil, and Microbe Interaction. Springer International Publishing; 2016.

20.

Fukai

Sakagami

Toguchi

, et al. Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. Anticancer Res. 2000;20(4):2525-2536.

21.

Yang

Zhang

Zhu

, et al. Separation and enrichment of major quinolizidine type alkaloids from Sophora alopecuroides using macroporous resins. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;945-946(01):17-22.

22.

Spedding

Ratty

Middleton

Jr.

Inhibition of reverse transcriptases by flavonoids. Antiviral Res. 1989;12(2):99-110.

23.

Wang

Cao

Efferth

, et al. Cytotoxic and new tetralone derivatives from Berchemia floribunda (Wall.) Brongn. Chem Biodivers. 2006;3(6):646-653.

24.

Lin

Shen

Chen

. Anti-inflammatory effect of heme oxygenase 1: glycosylation and nitric oxide inhibition in macrophages. J Cell Physiol. 2005;202(2):579-590.

25.

Zhang

Zhou

, et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin. 2001;22(2):183-186.

26.

Burow

Boue

Collins-Burow

, et al. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab. 2001;86(4):1750-1758.

27.

Chatterjee

Bhattacharya

Wonnemann

, et al. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 1998;63(6):499-510.

28.

Xue

Fan

, et al. Application of kushenin on patients with chronic hepatitis C after renal transplantation. Chin J Integr Med. 2008;14(3):167-172.

29.

Tan

Wolfender

Zhang

, et al. Acyl secoiridoids and antifungal constituents from Gentiana macrophylla. Phytochemistry. 1996;42(5):1305-1313.

30.

Sasaki

Higai

, et al. Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens. Planta Med. 2014;80(7):557-560.

31.

Leachianone G. PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. Accessed April 24, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Leachianone-G

32.

Cuendet

Hawthorne

, et al. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J Nat Prod. 2002;65(2):163-169.

33.

Peleg

Koder

Rokem

, et al. Phaseollin production in cell suspensions and whole plants of Phaseolus vulgaris. Plant Cell Tiss Organ Cult. 1987;9(3):207-215.

34.

(-)-Maackiain-3-O-glucosyl-6″-O-malonate. PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. Accessed April 24, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Maackiain-3-O-glucosyl-6_-O-malonate

35.

España

Ratnoff

. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med. 1983;102(1):31-45.

36.

Tomás-Barberán

Wollenweber

. Flavonoid aglycones from the leaf surfaces of some Labiatae species. Plant Syst Evol. 1990;173(09):109-118.

37.

Bergmann

. Die chemische Erforschung der Naturfarbstoffe. Ergebnisse der Physiologie und exper. Pharmakologie. 1933;35(1):158-300.

38.

Hegnauer

. Bignoniaceae. In: Rudolf

Minie

, eds.,Chemotaxonomie der Pflanzen. Lehrbücher und Monographien aus dem Gebiete der Exakten Wissenschaften. Birkhäuser; 1964:268-269.

39.

Peev

. Different substitution tendencies of leaf flavones in theVeronica hederifolia group (Scrophulariaceae). Plant Syst Evol. 1982;140(2):235-242.

40.

Lewis

Nichols

McMeekin

. Sterol and squalene content of a docosahexaenoic-acid-producing thraustochytrid: influence of culture age, temperature, and dissolved oxygen. Mar Biotechnol. 2001;3(5):439-447.

41.

Esslemont

. Beiträge zur pharmakologischen Wirkung von Abführmittel der Aloëderivatgruppe. Archiv f experiment Pathol u Pharmakol. 1899;43(3):274-285.

42.

Naidu

Singh

Kulkarni

. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology. 2003;167(4):418.

43.

Fujie

Ito

Maeda

. Acute cytogenetic effect of benzene on rat bone marrow cells in vivo and the effect of inducers or inhibitors of drug-metabolizing enzymes. Mutat Res. 1992;298(2):81-90.

44.

Everest

. Recent chemical investigations of the anthocyan pigments and their bearing upon the production of these pigments in plants. J Genet. 1915;4(4):361-367.

45.

Ralston

Christensen

Josh

. Use of mercurated fatty compounds as weed killers. Oil Soap. 1937;14(1):5-7.

46.

Dean

. Naturally occurring coumarins. In: Zechmeister

, ed. Fortschritte der Chemie Organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products/Progrès Dans La Chimie Des Substances Organiques Naturelles. Fortschritte der Chemie Organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products/Progrès Dans La Chimie Des Substances Organiques Naturelles. Springer; 1952:226.

47.

Oganesyan

. Minor flavonols from Dracocephalum multicaule. Chem Nat Compd. 2009;45(2):242-243.

48.

Liu

Guo

. Content determination and transfer rate investigation of effective component from FDQ particles (in Chinese). Chin J Exp Tradit Med Form. 2013;19(10):54-56.

49.

Pan

Zhang

, et al. Effect of different extraction technology on anti-inflammatory, analgesic and antipyretic action of Feiduqing (in Chinese). Chin J Exp Tradit Med Form. 2016;22(14):23-26.

50.

Chen

Peng

Liu

. The clinical observation of Feiduqing granule in treating patients with viral pneumonia hyperthermia (in Chinese). Pharm Clin Chin Mater Med. 2017;8(5):35-37.

51.

Liu

. Study on preparation technology of FDQ granules (In Chinese). J Chengdu Univ (Nat Sci Edit). 2014;33(2):110-114.

52.

Liu

. Effects of different preparation processes on in vitro antiviral activity of Feiduqing prescription (in Chinese). Chin J Exp Tradit Med Form. 2013;19(18):42-44.

53.

Liu

, et al. Study on mechanism for antipyretic effects of Shufeng Jiedu Capsule (in Chinese). Chin Tradit Herb Drugs. 2016;47(12):2040-2043.

54.

Chen

Xiao

. Effect of compatibility of Chinese Thorowax root and lobed Kudzuvine root on body temperature, serum content of IL-1β and activity of MPO of fever rats (in Chinese). Chin J Exp Tradit Med Form. 2011;17(5):207-209.

55.

Liu

Zhang

, et al. Effect of Bushen formulae on T helper cell 1, 17 and regulatory T cell in experimental autoimmune encephalomyelitis mice (in Chinese). Chin J Exp Tradit Med. Form. 2011;17(3):116-117.

56.

Helmke

Sugihara-Seki

Skalak

. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing (in Chinese). Blood. 1998;2(9):3007-3017.

57.

Loria

Dato

Graziani

. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008;13(5):625-627.

58.

Sun

Gao

Wang

. Antipyretic and anti-inflammatory effects of Mosla chinensis based on integration processing technology of origin (In Chinese). Chin Tradit Herb Drugs. 2018;49(20):26.

Identification of the Mechanism of Feiduqing on Viral Pneumonia Based on Network Pharmacology Analysis

Abstract

Keywords

Introduction

Materials and Methods

Screening of Chemical Ingredients in FDQ

Collection of Compound-Related Targets and VP-Related Targets

Construction and Analysis of the Protein–Protein Interaction (PPI) Network

Network Construction and Analysis

Preparation and Chemical Analysis of FDQ Extract

Materials

Determination of Potential Active Constituents of FDQ

Pharmacological Verification on Network Analysis

Materials

Animals

Animal Treatment and Tissue Preparation

Statistics

Results

Screening of Chemical Constituents of FDQ

Construction of Target Protein Interaction Network for FDQ in the Treatment of VP

Bioinformatics Analysis for FDQ in the Treatment of VP

Determination of Potential Active Constituents of FDQ

Pharmacological Verification

Antipyretic Effect

Antitussive Effect

Expectoration Effects

Discussion

Conclusion

Footnotes

Author Contributions

Declaration of Conflicting Interests

Funding

Ethical Approval

Statement of Human and Animal Rights

Statement of Informed Consent

Trial Registration

ORCID iD

References